Literature DB >> 20972737

Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus.

Yifei Zhang1, Xi Lu, Jie Hong, Menglei Chao, Weiqiong Gu, Weiqing Wang, Guang Ning.   

Abstract

It has long been proposed that elevation of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase (GGT) may be associated with insulin resistance (IR). In the present study, we aimed to investigate the association of the above mentioned liver enzymes with IR by using hyperinsulinemic euglycemic clamp, as well as their relationship with individual component of metabolic syndrome (MetS) in 95 newly diagnosed type 2 diabetes (T2DM) Chinese patients. All the diagnosed patients did not use drugs for treatment of diabetes or dyslipidemia previously and were divided into IR and non-IR groups. The results showed that IR group had significantly higher ALT, AST, and GGT (P<0.01, P<0.01, and P<0.05, respectively) compared with non-IR group. According to the individual MetS component, ALT and AST were significantly increased in patients with high blood pressure compared with those without (both P<0.001); ALT and GGT were increased in patients with high triglyceride (P<0.05 and P<0.01); AST was increased in patients with central obesity (P<0.05). In correlation analysis, a significant association was found between the three liver enzymes and clamp insulin sensitivity index (all P<0.001). In the linear regression analysis, ALT was the determinant of clamp ISI, independent of age, sex, BMI, and fasting and OGTT 2 h plasma glucose (P<0.0001). In conclusion, liver enzymes, especially ALT, were significantly associated with IR according to direct clamp assessment, which were independent of the traditional risk factors in diabetic patients; and individual liver enzymes may have different relationship with individual component of MetS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972737     DOI: 10.1007/s12020-010-9369-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  26 in total

1.  Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men.

Authors:  Sasiwarang Goya Wannamethee; Andrew Gerald Shaper; Lucy Lennon; Peter H Whincup
Journal:  Diabetes Care       Date:  2005-12       Impact factor: 19.112

2.  High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.

Authors:  Barbora Vozarova; Norbert Stefan; Robert S Lindsay; Aramesh Saremi; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

3.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Authors:  C Weyer; C Bogardus; D M Mott; R E Pratley
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

4.  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Authors:  C Weyer; P A Tataranni; C Bogardus; R E Pratley
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

5.  Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.

Authors:  Earl S Ford; Matthias B Schulze; Manuela M Bergmann; Claus Thamer; Hans-Georg Joost; Heiner Boeing
Journal:  Diabetes Care       Date:  2008-03-17       Impact factor: 19.112

Review 6.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.

Authors:  Catherine Postic; Jean Girard
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.

Authors:  Yifei Zhang; Xiaoying Li; Dajin Zou; Wei Liu; Jialin Yang; Na Zhu; Li Huo; Miao Wang; Jie Hong; Peihong Wu; Guoguang Ren; Guang Ning
Journal:  J Clin Endocrinol Metab       Date:  2008-04-08       Impact factor: 5.958

Review 8.  Metabolic syndrome, hyperinsulinemia, and cancer.

Authors:  Isabel R Hsu; Stella P Kim; Morvarid Kabir; Richard N Bergman
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

9.  Lycopus lucidus inhibits high glucose-induced vascular inflammation in human umbilical vein endothelial cells.

Authors:  Yun Jung Lee; Dae Gill Kang; Jin Sook Kim; Ho Sub Lee
Journal:  Vascul Pharmacol       Date:  2007-11-21       Impact factor: 5.773

10.  Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.

Authors:  Noriyuki Nakanishi; Kenji Suzuki; Kozo Tatara
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  23 in total

1.  Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection.

Authors:  Blaire E Burman; Peter Bacchetti; Claudia E Ayala; Nicholas Gelman; Jennifer Melgar; Mandana Khalili
Journal:  Liver Int       Date:  2014-09-20       Impact factor: 5.828

2.  Impact of weight-loss surgery and diabetes status on serum ALT levels.

Authors:  Dimitrios Xourafas; Ali Ardestani; Stanley W Ashley; Ali Tavakkoli
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

3.  An in vitro and in vivo study of the α-amylase activity of phaseolamin.

Authors:  Neire Moura de Gouveia; Fernanda Vieira Alves; Fabiana Barcelos Furtado; Danielli Luana Scherer; Antonio Vicente Mundim; Foued Salmen Espindola
Journal:  J Med Food       Date:  2014-03-20       Impact factor: 2.786

4.  Marked Influence of Adiposity on Laboratory Biomarkers in a Healthy Cohort of Children and Adolescents.

Authors:  Victoria Higgins; Arghavan Omidi; Houman Tahmasebi; Shervin Asgari; Kian Gordanifar; Michelle Nieuwesteeg; Khosrow Adeli
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

5.  New evidence for an association between liver enzymes and pancreatic islet β-cell dysfunction in young obese patients.

Authors:  Li Wang; Juanjuan Zhang; Bokai Wang; Yuwen Zhang; Jie Hong; Yifei Zhang; Weiqing Wang; Weiqiong Gu
Journal:  Endocrine       Date:  2013-04-03       Impact factor: 3.633

6.  Prevalence of insulin resistance and impaired glucose tolerance in a sample of obese Spanish children and adolescents.

Authors:  M P Bahíllo-Curieses; F Hermoso-López; M J Martínez-Sopena; P Cobreros-García; P García-Saseta; M Tríguez-García; J M Marugán-Miguelsanz
Journal:  Endocrine       Date:  2011-10-01       Impact factor: 3.633

Review 7.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

8.  Association of hematological parameters with metabolic syndrome in Beijing adult population: a longitudinal study.

Authors:  Li-Xin Tao; Xia Li; Hui-Ping Zhu; Da Huo; Tao Zhou; Lei Pan; Yan-Xia Luo; Wei Wang; Zhao-Ping Wang; Dong-Ning Chen; Li-Juan Wu; Xiu-Hua Guo
Journal:  Endocrine       Date:  2013-10-04       Impact factor: 3.633

9.  Elevated liver enzymes in individuals with undiagnosed diabetes in the U.S.

Authors:  Christie Y Jeon; Christian K Roberts; Catherine M Crespi; Zuo-Feng Zhang
Journal:  J Diabetes Complications       Date:  2013-05-14       Impact factor: 2.852

10.  Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.

Authors:  Xiaowen Liu; Ole-Petter R Hamnvik; John P Chamberland; Michael Petrou; Huizhi Gong; Costas A Christophi; David C Christiani; Stefanos N Kales; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-03-15       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.